Replimune Group's stock surged following Citigroup's upgrade to Overweight and a favorable FDA advisory panel vote supporting its advanced melanoma drug, RP1. The FDA panel voted 10-3 in favor of the drug's effectiveness in combination with nivolumab, despite some concerns about trial data. This positive regulatory step boosts investor confidence and could accelerate the drug's path to market for patients with advanced melanoma who have limited treatment options.
Micron's stock rose 13% following a strong earnings report showing 379% year-over-year revenue growth and 1,003% adjusted EPS growth, largely driven by AI demand. However, forward guidance indicates a slowdown, with Q1 revenue growth expected at 351%...
Bitcoin price hit a resistance near $87,220 before retreating to around $84,575, driven by whale investors selling over 30,000 BTC, worth about $2.52 billion. This selling pressure shifted attention to the $82,500 support zone, reinforced by technica...
In September, about 71% of tokenized stock trading volume on Uniswap occurred outside regular U.S. stock market hours, extending trading into nights, weekends, and holidays. Nearly half of these trades happened while U.S. stock exchanges were closed,...
Elon Musk recently hinted at the possibility of merging Tesla and SpaceX, two of the world's most valuable companies, during a public discussion. While no formal deal or board approval exists, Musk's comments have reignited speculation about the bene...
Brazil's presidential election is highly contested between leftist Lula and right-wing Bolsonaro, with markets favoring Bolsonaro due to his promise of fiscal discipline. Bolsonaro's potential win could lead to a rally in Brazilian bonds, currency, a...
